2023 World Conference on Lung Cancer (Posters)-P2.05. MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial

P2.05. MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial - PDF(Abstract)

Back to course

Pdf Summary

This document is a summary of a presentation titled "MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial" presented at the WCLC 2023 conference. The objective of the study was to identify predictive factors for immunotherapy in patients with LSCC, specifically focusing on the role of MAPK1/MAPK3 mutations in enhancing immunotherapy efficacy.<br /><br />The study examined the outcomes of a prospective, randomized phase II trial called the SQUINT trial. The trial compared the combination of nivolumab and ipilimumab (NI) versus nivolumab plus platinum-based chemotherapy (N-CT) in previously untreated advanced LSCC. Tumor samples from all participating patients were analyzed using comprehensive genomic profiling.<br /><br />The results showed that patients with mutations in the MAPK1/MAPK3 signaling genes had significantly longer progression-free survival (PFS) and overall survival (OS) compared to patients without these mutations. This effect was observed in patients with high tumor mutational burden (TMB) and high PD-L1 expression levels.<br /><br />Additionally, the study found that the risk of death was decreased in patients with bone metastases, current smokers, and individuals with high PD-L1 expression who were treated with NI compared to N-CT.<br /><br />In conclusion, mutations in the MAPK1/MAPK3 signaling genes were found to be predictive of improved PFS and OS in advanced LSCC patients treated with immunotherapy. These findings suggest that MAPK1/MAPK3 mutations could be used as a biomarker for identifying patients who are likely to benefit from immunotherapy.

Asset Subtitle

Gabriele Minuti

Meta Tag

Speaker Gabriele Minuti

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

MAPK1

MAPK3

mutations

immunotherapy

lung squamous cell carcinoma

SQUINT trial

WCLC 2023

predictive factors

progression-free survival

overall survival